Showing results (21-30 of 30) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 30 results.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|April 29, 2014
A pilot study: dose adaptation of capecitabine using mobile phone toxicity monitoring - supporting patients in their homesAndrew Weaver, Sharon B Love, Mark Larsen, et al.
Radiographics : a Review Publication of the Radiological Society of North America, Inc|March 22, 2007
Anatomic and functional imaging of metastatic carcinoid tumorsAndrew F Scarsbrook, Arul Ganeshan, Jane Statham, et al.
The Lancet. Oncology|September 24, 2016
Adjuvant capecitabine plus bevacizumab versus capecitabine alone in patients with colorectal cancer (QUASAR 2): an open-label, randomised phase 3 trialRachel S Kerr, Sharon Love, Eva Segelov, et al.
Endocrine-Related Cancer|December 13, 2018
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort studyEsben Andreas Carlsen, Nicola Fazio, Dan Granberg, et al.
The Lancet. Oncology|August 8, 2017
First-line selective internal radiotherapy plus chemotherapy versus chemotherapy alone in patients with liver metastases from colorectal cancer (FOXFIRE, SIRFLOX, and FOXFIRE-Global): a combined analysis of three multicentre, randomised, phase 3 trialsHarpreet S Wasan, Peter Gibbs, Navesh K Sharma, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 20, 2021
Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III TrialMary F Mulcahy, Armeen Mahvash, Marc Pracht, et al.
Scientific Data|July 16, 2024
The Tropical Andes Biodiversity Hotspot: A Comprehensive Dataset for the Mira-Mataje Binational BasinsMario H Yánez-Muñoz, Pablo Jarrín-V, Jorge Brito M, et al.
The Lancet. Oncology|April 4, 2018
3 versus 6 months of adjuvant oxaliplatin-fluoropyrimidine combination therapy for colorectal cancer (SCOT): an international, randomised, phase 3, non-inferiority trialTimothy J Iveson, Rachel S Kerr, Mark P Saunders, et al.
British Journal of Cancer|November 14, 2018
SCOT: a comparison of cost-effectiveness from a large randomised phase III trial of two durations of adjuvant Oxaliplatin combination chemotherapy for colorectal cancerJosé Robles-Zurita, Kathleen A Boyd, Andrew H Briggs, et al.
Health Technology Assessment (Winchester, England)|December 20, 2019
3-month versus 6-month adjuvant chemotherapy for patients with high-risk stage II and III colorectal cancer: 3-year follow-up of the SCOT non-inferiority RCTTimothy Iveson, Kathleen A Boyd, Rachel S Kerr, et al.
Pageof 3